Beyond lymph node staging: Molecular predictors of outcome in breast cancer

Surgical Oncology Clinics of North America

Volumn 14, Issue 1, 2005, Pages 69-84

  Sheldon, David G ^a  

^a GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; STEROID RECEPTOR; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER; UROKINASE;

ADJUVANT CHEMOTHERAPY; AXILLARY LYMPH NODE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENOME; HISTOLOGY; HORMONAL THERAPY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MASTECTOMY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; SENTINEL LYMPH NODE BIOPSY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; TREATMENT OUTCOME;

EID: 8444235565     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2004.07.007     Document Type: Review

References (103)

1. M.H. Galea, R.W. Blamey, C.E. Elston, and I.O. Ellis The Nottingham Prognostic Index in primary breast cancer Breast Cancer Res Treat 22 1992 207 219
2. I. Balslev, C.K. Axelsson, K. Zedeler, B.B. Rasmussen, B. Carstensen, and H.T. Mouridsen The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) Breast Cancer Res Treat 32 1994 281 290
3. J.R. Harris, M.E. Lippman, U. Veronesi, and W. Willett Breast cancer (3) N Engl J Med 327 1992 473 480
4. D.C. Allred, J.M. Harvey, M. Berardo, and G.M. Clark Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 1998 155 168
5. A. Goldhirsch, J.H. Glick, R.D. Gelber, A.S. Coates, and H.J. Senn Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer J Clin Oncol 19 2001 3817 3827
6. Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group Lancet 352 1998 930 942
7. B.F. Cole, R.D. Gelber, S. Gelber, A.S. Coates, and A. Goldhirsch Polychemotherapy for early breast cancer: an overview of the randomized clinical trials with quality-adjusted survival analysis Lancet 358 2001 277 286
8. P. Eifel, J.A. Axelson, and J. Costa National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000 J Natl Cancer Inst 93 2001 979 989
9. B. Fisher, C. Redmond, and N.V. Dimitrov A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors N Engl J Med 320 1989 473 478
10. E.G. Mansour, R. Gray, and A.H. Shatila Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis-an intergroup study J Clin Oncol 16 1998 3486 3492
11. N. Wald, C. Frost, and H. Cuckle Breast cancer screening: the current position BMJ 302 1991 845 846
12. S.W. Fletcher, and J.G. Elmore Clinical practice. Mammographic screening for breast cancer N Engl J Med 348 2003 1672 1680
13. L. Tabar, R.A. Smith, and B. Vitak Mammographic screening: a key factor in the control of breast cancer Cancer J 9 2003 15 27
14. C.L. Carter, C. Allen, and D.E. Henson Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 1989 181 187
15. M.J. Silverstein, E.D. Gierson, J.R. Waisman, W.J. Colburn, and P. Gamagami Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability J Am Coll Surg 180 1995 700 704
16. S. Koscielny, M. Tubiana, and M.G. Le Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination Br J Cancer 49 1984 709 715
17. E.R. Fisher, R. Sass, and B. Fisher Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no. 4). X. Discriminants for tenth year treatment failure Cancer 53 1984 712 723
18. D.E. Henson, L. Ries, L.S. Freedman, and M. Carriaga Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index Cancer 68 1991 2142 2149
19. A.M. Neville, R. Bettelheim, and R.D. Gelber Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1992 696 705
20. V. Le Doussal, M. Tubiana-Hulin, S. Friedman, K. Hacene, F. Spyratos, and M. Brunet Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas Cancer 64 1989 1914 1921
21. S.E. Pinder, I.O. Ellis, M. Galea, S. O'Rouke, R.W. Blamey, and C.W. Elston Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up Histopathology 24 1994 41 47
22. B.W. Davis, R. Gelber, and A. Goldhirsch Prognostic significance of peritumoral vessel invasion in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis Hum Pathol 16 1985 1212 1218
23. R. Bettelheim, H.G. Penman, H. Thornton-Jones, and A.M. Neville Prognostic significance of peritumoral vascular invasion in breast cancer Br J Cancer 50 1984 771 777
24. C.S. Woo, H. Silberman, and S.K. Nakamura Lymph node status combined with lymphovascular invasion creates a more powerful tool for predicting outcome in patients with invasive breast cancer Am J Surg 184 2002 337 340
25. R. Lauria, F. Perrone, and C. Carlomagno The prognostic value of lymphatic and blood vessel invasion in operable breast cancer Cancer 76 1995 1772 1778
26. P. Viens, J. Jacquemier, and V.J. Bardou Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy Breast Cancer Res Treat 54 1999 205 212
27. C.K. Axelsson, H.T. Mouridsen, and K. Zedeler Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG) Eur J Cancer 28A 1992 1415 1418
28. O. Mathiesen, J. Carl, O. Bonderup, and J. Panduro Axillary sampling and the risk of erroneous staging of breast cancer. An analysis of 960 consecutive patients Acta Oncol 29 1990 721 725
29. R.A. Sacre Clinical evaluation of axillary lymph nodes compared to surgical and pathological findings Eur J Surg Oncol 12 1986 169 173
30. D.J. Ferguson, P. Meier, T. Karrison, P.J. Dawson, F.H. Straus, and F.E. Lowenstein Staging of breast cancer and survival rates. An assessment based on 50 years of experience with radical mastectomy JAMA 248 1982 1337 1341
31. U. Veronesi, N. Cascinelli, and L. Mariani Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer N Engl J Med 347 2002 1227 1232
32. U. Veronesi, A. Luini, V. Galimberti, S. Marchini, V. Sacchini, and F. Rilke Extent of metastatic axillary involvement in 1446 cases of breast cancer Eur J Surg Oncol 16 1990 127 133
33. M. Overgaard, P.S. Hansen, and J. Overgaard Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial N Engl J Med 337 1997 949 955
34. J. Ragaz, S.M. Jackson, and N. Le Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer N Engl J Med 337 1997 956 962
35. B. Fisher, C. Redmond, and E.R. Fisher Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation N Engl J Med 312 1985 674 681
36. B. Fisher, J.H. Jeong, S. Anderson, J. Bryant, E.R. Fisher, and N. Wolmark Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation N Engl J Med 347 2002 567 575
37. D. Larson, M. Weinstein, and I. Goldberg Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy Int J Radiat Oncol Biol Phys 12 1986 1575 1582
38. S.B. Edge, J.C. Niland, and M.A. Bookman Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers J Natl Cancer Inst 95 2003 1514 1521
39. A.M. Thompson, R.A. Elton, R.A. Hawkins, U. Chetty, and C.M. Steel PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer Br J Cancer 77 1998 492 496
40. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Lancet 339 1992 1 15
41. I.L. Andrulis, S.B. Bull, and M.E. Blackstein neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group J Clin Oncol 16 1998 1340 1349
42. G. Riou, M.C. Mathieu, and M. Barrois c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients Int J Cancer 95 2001 266 270
43. M.F. Press, D.J. Slamon, K.J. Flom, J. Park, J.Y. Zhou, and L. Bernstein Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 2002 3095 3105
44. D.R. Ciocca, F.K. Fujimura, and A.K. Tandon Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers J Natl Cancer Inst 84 1992 1279 1282
45. A. Borg, A.K. Tandon, and H. Sigurdsson HER-2/neu amplification predicts poor survival in node-positive breast cancer Cancer Res 50 1990 4332 4337
46. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
47. J. Chang, T.J. Powles, and D.C. Allred Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 1999 3058 3063
48. M. Agrup, O. Stal, K. Olsen, and S. Wingren C-erbB-2 overexpression and survival in early onset breast cancer Breast Cancer Res Treat 63 2000 23 29
49. L.C. Hartmann, J.N. Ingle, and L.E. Wold Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol Cancer 74 1994 2956 2963
50. J.R. Sainsbury, J.R. Farndon, G.K. Needham, A.J. Malcolm, and A.L. Harris Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer Lancet 1 1987 1398 1402
51. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
52. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
53. C. Vogel, M.A. Cobleigh, and D. Tripathy First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report Eur J Cancer 37 Suppl 1 2001 25 29
54. D. Gancberg, A. Di Leo, and F. Cardoso Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 2002 1036 1043
55. M.S. Greenblatt, W.P. Bennett, M. Hollstein, and C.C. Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 1994 4855 4878
56. J. Overgaard, M. Yilmaz, P. Guldberg, L.L. Hansen, and J. Alsner TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer Acta Oncol 39 2000 327 333
57. T. Jansson, M. Inganas, and S. Sjogren p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings J Clin Oncol 13 1995 2745 2751
58. P.D. Pharoah, N.E. Day, and C. Caldas Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis Br J Cancer 80 1999 1968 1973
59. S.B. Bull, H. Ozcelik, and D. Pinnaduwage The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer J Clin Oncol 22 2004 86 96
60. P.L. Porter, K.E. Malone, and P.J. Heagerty Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nat Med 3 1997 222 225
61. R. Donnellan, I. Kleinschmidt, and R. Chetty Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications Hum Pathol 32 2001 89 94
62. S. Fredersdorf, J. Burns, and A.M. Milne High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers Proc Natl Acad Sci USA 94 1997 6380 6385
63. A. Tsuchiya, G.J. Zhang, and M. Kanno Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer J Surg Oncol 70 1999 230 234
64. J.A. Foekens, H.A. Peters, and M.P. Look The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients Cancer Res 60 2000 636 643
65. M.P. Look, W.L. van Putten, and M.J. Duffy Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients J Natl Cancer Inst 94 2002 116 128
66. S.W. Beenken, W.E. Grizzle, and D.R. Crowe Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53 Ann Surg 233 2001 630 638
67. S. Braun, K. Pantel, and P. Muller Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer N Engl J Med 342 2000 525 533
68. K. Pantel, V. Muller, M. Auer, N. Nusser, N. Harbeck, and S. Braun Detection and clinical implications of early systemic tumor cell dissemination in breast cancer Clin Cancer Res 9 2003 6326 6334
69. J.Y. Pierga, C. Bonneton, and A. Vincent-Salomon Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients Clin Cancer Res 10 2004 1392 1400
70. J.L. Mansi, U. Berger, and T. McDonnell The fate of bone marrow micrometastases in patients with primary breast cancer J Clin Oncol 7 1989 445 449
71. O. Solakoglu, C. Maierhofer, and G. Lahr Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors Proc Natl Acad Sci USA 99 2002 2246 2251
72. P. Muller, D. Weckermann, G. Riethmuller, and G. Schlimok Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization Cancer Genet Cytogenet 88 1996 8 16
73. S. Braun, C. Kentenich, and W. Janni Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients J Clin Oncol 18 2000 80 86
74. S. Braun, B.S. Cevatli, and C. Assemi Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy J Clin Oncol 19 2001 1468 1475
75. G. Gebauer, T. Fehm, E. Merkle, E.P. Beck, N. Lang, and W. Jager Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up J Clin Oncol 19 2001 3669 3674
76. C.A. Klein, O. Schmidt-Kittler, J.A. Schardt, K. Pantel, M.R. Speicher, and G. Riethmuller Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells Proc Natl Acad Sci USA 96 1999 4494 4499
77. N. Ditsch, B. Mayer, M. Rolle, M. Untch, F.W. Schildberg, and I. Funke Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients Recent Results Cancer Res 162 2003 141 147
78. B. Fisher Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture Cancer Res 40 1980 3863 3874
79. C.A. Klein, T.J. Blankenstein, and O. Schmidt-Kittler Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer Lancet 360 2002 683 689
80. O. Schmidt-Kittler, T. Ragg, and A. Daskalakis From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression Proc Natl Acad Sci USA 100 2003 7737 7742
81. C.A. Klein Gene expression signatures, cancer cell evolution and metastatic progression Cell Cycle 3 2004 29 31
82. J.L. Mansi, D. Easton, and U. Berger Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up Eur J Cancer 27 1991 1552 1555
83. J.L. Mansi, H. Gogas, J.M. Bliss, J.C. Gazet, U. Berger, and R.C. Coombes Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study Lancet 354 1999 197 202
84. I.J. Diel, M. Kaufmann, and S.D. Costa Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status J Natl Cancer Inst 88 1996 1652 1658
85. G. Wiedswang, E. Borgen, and R. Karesen Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer J Clin Oncol 21 2003 3469 3478
86. S. Braun, G. Schlimok, and I. Heumos ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients Cancer Res 61 2001 1890 1895
87. C.M. Perou, T. Sorlie, and M.B. Eisen Molecular portraits of human breast tumours Nature 406 2000 747 752
88. T. Sorlie, R. Tibshirani, and J. Parker Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 2003 8418 8423
89. J.E. Staunton, D.K. Slonim, and H.A. Coller Chemosensitivity prediction by transcriptional profiling Proc Natl Acad Sci USA 98 2001 10787 10792
90. T. Sorlie, C.M. Perou, and R. Tibshirani Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874
91. S. Gruvberger, M. Ringner, and Y. Chen Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Res 61 2001 5979 5984
92. J.C. Chang, E.C. Wooten, and A. Tsimelzon Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362 369
93. T.A. Buchholz, D.N. Stivers, and J. Stec Global gene expression changes during neoadjuvant chemotherapy for human breast cancer Cancer J 8 2002 461 468
94. I. Hedenfalk, D. Duggan, and Y. Chen Gene-expression profiles in hereditary breast cancer N Engl J Med 344 2001 539 548
95. W.F. Symmans, M. Ayers, and E.A. Clark Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma Cancer 97 2003 2960 2971
96. A. Ahr, T. Karn, and C. Solbach Identification of high risk breast-cancer patients by gene expression profiling Lancet 359 2002 131 132
97. L.J. van't Veer, H. Dai, and M.J. van de Vijver Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536
98. M.J. van de Vijver, Y.D. He, and L.J. van't Veer A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009
99. B. Weigelt, A.M. Glas, L.F. Wessels, A.T. Witteveen, J.L. Peterse, and L.J. van't Veer Gene expression profiles of primary breast tumors maintained in distant metastases Proc Natl Acad Sci USA 100 2003 15901 15905
100. E.S. Lander, L.M. Linton, and B. Birren Initial sequencing and analysis of the human genome Nature 409 2001 860 921
101. J.C. Venter, M.D. Adams, and E.W. Myers The sequence of the human genome Science 291 2001 1304 1351
102. W. Janni, F. Hepp, and D. Rjosk The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence Cancer 92 2001 46 53
103. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, and M. Cronin Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients - NSABP studies B-20 and B-14 Oncology Times 26 Suppl 2004 2 3